Drug
Trifarotene
Trifarotene: highest development phase Post-Market, developed by Galderma. 3 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Galderma
Trials
| Drug | Phase | Indication |
|---|---|---|
| Trifarotene Cream NCT05089708 | Post-Market | Acne Vulgaris |
| Trifarotene NCT07186413 | Phase 3 | Acne Vulgaris |
| Trifarotene NCT03915860 | Phase 3 | Acne Vulgaris |
Latest
No recent events.
Follow Trifarotene on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.